文献速递肿瘤 PET/CT核素与放射性配体治疗

阿帕他胺联合去势后PSMA阳性病灶巩固治疗在转移性激素敏感性前列腺癌中的前瞻性II期单臂试验

Consolidative therapy for PSMA-avid lesions after 3 cycles of apalutamide plus androgen deprivation in metastatic hormone-sensitive prostate cancer: A prospective phase 2 single-arm trial.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-06-08

CHAMPION试验为多中心单臂II期研究,纳入48例新诊断且常规影像 distant metastases ≤10个的mHSPC患者,基线及3周期阿帕他胺联合去势后行PSMA PET/CT,对≤10个PSMA阳性转移灶者给予巩固治疗,6周期后不可测PSA率95.8%(46/48;95%CI 86.0%-98.8%),≥3级皮疹仅2例(4.2%)。

要点

  • 3周期阿帕他胺联合去势后PSMA PET/CT引导巩固治疗,6周期不可测PSA率达95.8%。
  • ≥3级不良事件仅皮疹2例(4.2%),安全性可控。
  • 远处淋巴结转移灶治疗反应率最高93.3%,椎体/骨盆骨转移78.5%,其他骨转移50.0%。

核心结论

  • PSMA PET/CT引导的残留病灶巩固治疗联合强化系统治疗,在新诊断且≤10个远处转移的mHSPC患者中与高PSA缓解率和可控不良事件相关。

研究设计与样本

  • CHAMPION试验(NCT05717582)为多中心、单臂、II期研究,2023年3月至2024年8月纳入新诊断mHSPC且常规影像 distant metastases ≤10个的患者。
  • 患者接受3周期阿帕他胺联合去势后行PSMA PET/CT,PSMA阳性转移灶≤10个者接受根治性前列腺切除或放疗,并对剩余PSMA阳性病灶行立体定向体部放疗。
  • 共纳入48例患者,中位基线PSA为56.8 ng/mL;主要终点为6周期阿帕他胺后不可测PSA(≤0.2 ng/mL)比例。

主要发现

  • 基线常规影像显示1-3个远处转移31例(64.6%),4-10个17例(35.4%)。
  • 基线PSMA PET/CT显示1-3个远处转移17例(35.4%),4-5个8例(16.7%),>5个23例(47.9%)。
  • 最常见PSMA阳性部位为骨(47/48,97.9%)、区域淋巴结(28/48,58.3%)和远处淋巴结(15/48,31.3%)。
  • 3周期后2例PSMA阳性转移灶>10个继续阿帕他胺,其余46例≤10个接受巩固治疗。
  • 6周期后总体不可测PSA率为95.8%(46/48;95%CI 86.0%-98.8%),较3周期后的66.7%(32/48)提高29.1%。

关键数值与推荐

  • 主要终点为6周期阿帕他胺后不可测PSA(≤0.2 ng/mL)比例,达95.8%(46/48;95%CI 86.0%-98.8%)。
  • PSMA阳性转移灶>10个者继续阿帕他胺,≤10个者接受根治性前列腺切除或放疗,并对剩余PSMA阳性病灶行立体定向体部放疗。

临床怎么用

  • 对新诊断且常规影像 distant metastases ≤10个的mHSPC患者,可在3周期阿帕他胺联合去势后行PSMA PET/CT评估残留病灶。
  • 根据PSMA PET/CT显示的转移灶数目(>10或≤10)决定继续系统治疗或联合巩固治疗。

局限性

  • 本研究为单臂II期试验,未设对照组,结论需随机对照研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metastatic hormone-sensitive prostate cancer (mHSPC) with limited metastatic burden presents a therapeutic challenge, with residual PSMA-avid disease post-androgen receptor pathway inhibitor (ARPI) treatment poorly characterized in prospective studies. PATIENTS AND METHODS: The CHAMPION trial (NCT05717582) was a multicenter, single-arm, phase II study designed to evaluate the efficacy and safety of a response-adapted treatment strategy incorporating consolidative therapy (TCT) for PSMA-avid residual resistant clones following ARPI in newly diagnosed mHSPC patients with ≤ 10 conventional imaging (CI)-defined distant metastases from March 2023 to August 2024. PSMA PET/CT scans were performed at baseline and after three cycles of apalutamide plus castration. Patients with > 10 PSMA-positive distant metastases continued apalutamide therapy, while those with ≤ 10 metastases underwent radical prostatectomy or radiotherapy, with stereotactic body radiotherapy targeting all remaining PSMA-positive lesions, if present. The primary endpoint was the proportion of patients achieving an undetectable PSA level (≤ 0.2 ng/mL) after 6 cycles of apalutamide. RESULTS: A total of 48 patients with a median baseline PSA level of 56.8 ng/mL were enrolled. Baseline CI revealed 1-3 distant metastases in 31 patients (64.6%) and 4-10 in 17 patients (35.4%). Baseline PSMA PET/CT showed 1-3 distant metastases in 17 patients (35.4%), 4-5 in 8 patients (16.7%), and > 5 in 23 patients (47.9%); the most common PSMA-positive sites were bone (47/48, 97.9%), regional lymph nodes (28/48, 58.3%), and distant lymph nodes (15/48, 31.3%). After 3-cycle of apalutamide, two patients with > 10 PSMA-positive metastases continued apalutamide, while the remaining 46 with ≤ 10 metastases received TCT. After six cycles, the overall undetectable PSA rate was 95.8% (46/48; 95% CI: 86.0%-98.8%), a 29.1% increase from the 66.7% (32/48) observed after three cycles. Only two patients (4.2%) experienced grade ≥ 3 rash. Post-treatment, distant lymph node metastases showed the highest response rate at 93.3% (140/150), followed by vertebral column and pelvis bone metastases at 78.5% (255/325), and other bone metastases at 50.0% (58/116), with significant differences between each metastatic site pair (p < 0.0001). CONCLUSIONS: This novel treatment paradigm, integrating PSMA PET/CT-guided TCT for residual lesions with intensified systemic therapy, was associated with a high PSA response rate and manageable adverse event profile in newly diagnosed mHSPC patients with ≤ 10 distant metastases. TRIAL REGISTRATION: NCT05717582. Registered: 8 February 2023.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Pan J, Wang B, Zhu B, et al. Consolidative therapy for PSMA-avid lesions after 3 cycles of apalutamide plus androgen deprivation in metastatic hormone-sensitive prostate cancer: A prospective phase 2 single-arm trial. Eur J Nucl Med Mol Imaging. 2026. PMID: 42252348. doi:10.1007/s00259-026-07982-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。